PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
MH Qazilbash, E Wieder, PF Thall, X Wang, R Rios… - Leukemia, 2017 - nature.com
Abstract PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil
elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes (CTLs) that
preferentially kill leukemia and contribute to cytogenetic remission. To evaluate safety,
elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes (CTLs) that
preferentially kill leukemia and contribute to cytogenetic remission. To evaluate safety,
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to ＞99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论